Xenogen Announces Licensing Agreement With MIR

Xenogen announced a partnership with MIR Preclinical Services (MIR), a contract research organization, for the purchase and sublicense of Xenogen's biophotonic imaging, or real-time in vivo imaging, technologies. MIR is now authorized to use Xenogen's proprietary technology to conduct preclinical research for pharmaceutical and biotech companies, across a variety of therapeutic areas excluding infectious diseases.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=228621)